NCT06746961 2024-12-24Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyThe First Affiliated Hospital of Zhengzhou UniversityPhase 1/2 Not yet recruiting49 enrolled